Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

CPRX Catalyst Pharmaceuticals Inc

Price (delayed)

$24.63

Market cap

$3B

P/E Ratio

14.93

Dividend/share

N/A

EPS

$1.65

Enterprise value

$2.43B

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK ...

Highlights
The EPS has soared by 175% year-on-year and by 20% since the previous quarter
Catalyst Pharmaceuticals's equity has increased by 41% YoY and by 9% QoQ

Key stats

What are the main financial stats of CPRX
Market
Shares outstanding
121.98M
Market cap
$3B
Enterprise value
$2.43B
Valuations
Price to earnings (P/E)
14.93
Price to book (P/B)
3.77
Price to sales (P/S)
5.6
EV/EBIT
9.39
EV/EBITDA
8.18
EV/Sales
4.54
Earnings
Revenue
$534.65M
Gross profit
$460.41M
Operating income
$231.37M
Net income
$197.35M
EBIT
$258.46M
EBITDA
$296.55M
Free cash flow
$267.57M
Per share
EPS
$1.65
EPS diluted
$1.57
Free cash flow per share
$2.2
Book value per share
$6.54
Revenue per share
$4.4
TBVPS
$6.27
Balance sheet
Total assets
$908.87M
Total liabilities
$114.59M
Debt
$2.68M
Equity
$794.28M
Working capital
$574.07M
Liquidity
Debt to equity
0
Current ratio
6.14
Quick ratio
5.84
Net debt/EBITDA
-1.95
Margins
EBITDA margin
55.5%
Gross margin
86.1%
Net margin
36.9%
Operating margin
43.3%
Efficiency
Return on assets
24.4%
Return on equity
28.3%
Return on invested capital
400.2%
Return on capital employed
32.4%
Return on sales
48.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CPRX stock price

How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
1.07%
1 week
3.36%
1 month
9.37%
1 year
49.36%
YTD
18.02%
QTD
1.57%

Financial performance

How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$534.65M
Gross profit
$460.41M
Operating income
$231.37M
Net income
$197.35M
Gross margin
86.1%
Net margin
36.9%
CPRX financials
The company's operating income has surged by 195% YoY and by 19% QoQ
Catalyst Pharmaceuticals's net margin has surged by 134% YoY and by 11% QoQ
The operating margin has soared by 128% YoY and by 9% QoQ
The revenue rose by 30% YoY and by 9% QoQ

Price vs fundamentals

How does CPRX's price correlate with its fundamentals
Price vs fundamentals
Earnings waterfall
Price vs fair value

Growth

What is Catalyst Pharmaceuticals's growth rate over time
CPRX growth chart

Valuation

What is Catalyst Pharmaceuticals stock price valuation
P/E
14.93
P/B
3.77
P/S
5.6
EV/EBIT
9.39
EV/EBITDA
8.18
EV/Sales
4.54
Valuation vs average
Price to earnings (P/E)
The EPS has soared by 175% year-on-year and by 20% since the previous quarter
The stock's P/E is 17% less than its last 4 quarters average of 18.0 and 4.9% less than its 5-year quarterly average of 15.7
Price to book (P/B)
Catalyst Pharmaceuticals's equity has increased by 41% YoY and by 9% QoQ
The stock's price to book (P/B) is 11% more than its last 4 quarters average of 3.4 and 4.7% more than its 5-year quarterly average of 3.6
Price to sales (P/S)
The revenue rose by 30% YoY and by 9% QoQ
The price to sales (P/S) is 17% higher than the 5-year quarterly average of 4.8 and 12% higher than the last 4 quarters average of 5.0

Efficiency

How efficient is Catalyst Pharmaceuticals business performance
The ROIC has soared by 192% year-on-year and by 21% since the previous quarter
The ROS has soared by 130% year-on-year and by 10% since the previous quarter
CPRX's return on assets has surged by 85% year-on-year and by 11% since the previous quarter
The ROE has soared by 81% YoY and by 11% from the previous quarter

Dividends

What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPRX.

Financial health

How did Catalyst Pharmaceuticals financials performed over time
Assets vs liabilities
The total assets is up by 41% year-on-year and by 7% since the previous quarter
The total liabilities rose by 34% YoY but it fell by 7% QoQ
Debt vs equity
Catalyst Pharmaceuticals's debt is 100% lower than its equity
CPRX's debt to equity has dropped by 100% year-on-year
Catalyst Pharmaceuticals's equity has increased by 41% YoY and by 9% QoQ
Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.